| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 29/05/2024 | 22:43 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NUVL | Nuvalent Inc |
| 29/05/2024 | 12:30 | PR Newswire (US) | Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference | NASDAQ:NUVL | Nuvalent Inc |
| 16/05/2024 | 22:10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NUVL | Nuvalent Inc |
| 16/05/2024 | 22:01 | PR Newswire (US) | Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 | NASDAQ:NUVL | Nuvalent Inc |
| 09/05/2024 | 12:46 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:NUVL | Nuvalent Inc |
| 09/05/2024 | 12:30 | PR Newswire (US) | Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results | NASDAQ:NUVL | Nuvalent Inc |
| 08/04/2024 | 22:30 | PR Newswire (US) | Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | NASDAQ:NUVL | Nuvalent Inc |
| 05/03/2024 | 22:52 | PR Newswire (US) | Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 | NASDAQ:NUVL | Nuvalent Inc |
| 27/02/2024 | 13:00 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NUVL | Nuvalent Inc |
| 27/02/2024 | 12:42 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NUVL | Nuvalent Inc |
| 27/02/2024 | 12:30 | PR Newswire (US) | Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:NUVL | Nuvalent Inc |
| 27/02/2024 | 12:15 | PR Newswire (US) | Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 | NASDAQ:NUVL | Nuvalent Inc |
| 12/02/2024 | 12:30 | PR Newswire (US) | Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors | NASDAQ:NUVL | Nuvalent Inc |
| 01/02/2024 | 12:30 | PR Newswire (US) | Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | NASDAQ:NUVL | Nuvalent Inc |
| 08/01/2024 | 12:30 | PR Newswire (US) | Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones | NASDAQ:NUVL | Nuvalent Inc |
| 26/12/2023 | 22:31 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:NUVL | Nuvalent Inc |
| 21/12/2023 | 12:30 | PR Newswire (US) | Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:NUVL | Nuvalent Inc |
| 14/11/2023 | 12:30 | PR Newswire (US) | Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results | NASDAQ:NUVL | Nuvalent Inc |
| 01/11/2023 | 11:30 | PR Newswire (US) | Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day | NASDAQ:NUVL | Nuvalent Inc |
| 17/10/2023 | 22:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:NUVL | Nuvalent Inc |
| 17/10/2023 | 03:55 | PR Newswire (US) | Nuvalent Announces Pricing of Public Offering of Common Stock | NASDAQ:NUVL | Nuvalent Inc |
| 16/10/2023 | 13:30 | PR Newswire (US) | Nuvalent Announces Public Offering of Common Stock | NASDAQ:NUVL | Nuvalent Inc |
| 13/10/2023 | 12:30 | PR Newswire (US) | Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC | NASDAQ:NUVL | Nuvalent Inc |
| 04/10/2023 | 18:21 | PR Newswire (US) | Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile | NASDAQ:NUVL | Nuvalent Inc |
| 18/09/2023 | 12:30 | PR Newswire (US) | Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium | NASDAQ:NUVL | Nuvalent Inc |
| 05/09/2023 | 12:30 | PR Newswire (US) | Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors | NASDAQ:NUVL | Nuvalent Inc |
| 31/08/2023 | 12:30 | PR Newswire (US) | Nuvalent to Participate in Upcoming September Investor Conferences | NASDAQ:NUVL | Nuvalent Inc |
| 10/08/2023 | 12:30 | PR Newswire (US) | Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results | NASDAQ:NUVL | Nuvalent Inc |
| 01/08/2023 | 12:30 | PR Newswire (US) | Nuvalent to Participate in Upcoming August Investor Conferences | NASDAQ:NUVL | Nuvalent Inc |
| 20/06/2023 | 22:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:NUVL | Nuvalent Inc |